Pharmacogenomics in Thailand: Cost, Top Clinics & What to Expect

Pharmacogenomic testing examines variants in genes encoding drug-metabolising enzymes, transporters, and receptor targets. Key gene families — CYP2D6, CYP2C19, CYP3A4, VKORC1, DPYD, TPMT among others — determine how quickly you activate or clear specific medications. A blood draw or cheek swab provides the DNA needed to genotype these loci and classify you as a poor, intermediate, normal, or ultra-rapid metaboliser for each pathway.

The clinical value is concrete. If you are a poor metaboliser of CYP2D6, codeine will not work for you — it cannot be converted to its active form. If you are an ultra-rapid metaboliser of CYP2C19, clopidogrel may not provide adequate antiplatelet protection. These are not theoretical concerns — they directly affect whether medications help, harm, or do nothing. The 2023 Lancet trial (PREPARE study) demonstrated that pharmacogenomic-guided prescribing reduced adverse drug reactions by 30% compared to standard care.

Pharmacogenomic testing in Thailand typically costs between $400 and $650, depending on scope — a targeted 10–15 gene panel at the lower end, a comprehensive 200+ medication profile at the higher end. Both include genotyping, analysis, written report, specialist consultation, and prescriber summary.

The total covers initial consultation, sample collection, accredited laboratory genotyping, drug–gene interaction mapping, a personalised medication guide, a specialist results consultation, and a clinical summary letter for your home doctor. A care coordinator supports you throughout.

Scope is the main variable. A targeted panel covering the most impactful pharmacogenes costs less than a comprehensive profile mapping metaboliser status against hundreds of medications. Adding a detailed medication review for patients on multiple current drugs increases the total. Your specialist recommends the scope that matches your needs.

Pricing varies by the complexity and scope of the procedure. Typical ranges at our partner hospitals in Thailand:

• Targeted pharmacogenomics panel (psychiatric medications): $400–$480 — tests genes affecting metabolism of antidepressants, anxiolytics, and mood stabilisers
• Broad pharmacogenomics panel (multi-drug class): $480–$560 — covers cardiac, pain, oncology, and psychiatric drug metabolism
• Comprehensive pharmacogenomics with clinical consultation: $560–$650 — full panel plus a specialist review to adjust your current medications

Exact pricing is confirmed after your consultation and treatment plan are finalised.

Pharmacogenomic testing in Thailand costs 50–70% less than equivalent services in the US ($800–$1,600), Australia (A$700–A$1,400), and UK (£650–£1,200). The savings come from lower clinical costs with no reduction in genotyping accuracy, guideline alignment, or interpretation quality.

Immediately. The test involves a blood draw or cheek swab — nothing that affects travel. Many patients collect their sample during a health screening or clinic visit and fly home the same day. Results are delivered remotely.

No. Genotyping takes two to three weeks. The results consultation and medication review can be conducted via secure video call from anywhere. Staying in Thailand for results is not necessary.

Share the clinical summary with your prescribing physician at home. Every time a new medication is considered, your doctor can check it against your pharmacogenomic profile. The report functions as a permanent prescribing reference — a single test that keeps providing value for the rest of your life.

Yes. The 2023 PREPARE study (published in The Lancet) demonstrated that pharmacogenomic-guided prescribing reduced adverse drug reactions by 30% compared to standard care. CPIC and DPWG maintain continuously updated, peer-reviewed prescribing guidelines for dozens of drug–gene pairs. The evidence base is robust and growing, which is why major health systems including the NHS are integrating pharmacogenomics into routine care.

Your report is formatted with clinician-friendly language and references established CPIC/DPWG guidelines. It includes a clinical summary letter specifically for prescribers. Most physicians are familiar with pharmacogenomics or can easily interpret the actionable recommendations. Your Thai specialist is available for a collegial discussion with your home doctor if additional context is needed.

If your genotype indicates that a current medication may need dose adjustment or substitution, the recommendation is communicated through the prescriber summary — never implemented without your doctor's involvement. Your pharmacogenomics specialist prioritises the most clinically significant interactions and presents them with supporting evidence so your prescriber can make informed decisions.

Our partner clinics use accredited laboratories running validated genotyping platforms calibrated against CDC GeT-RM reference materials. The same accreditation and validation standards apply at leading Western pharmacogenomics services. Clinics are staffed by specialists with specific training in pharmacogenomics — not general practitioners interpreting results from a template.

The specialists running these programmes have training in clinical pharmacogenomics, pharmacology, or precision medicine. They understand both the laboratory science and the clinical application — which drug–gene interactions are high-priority, which are theoretical, and how to communicate recommendations effectively to prescribers who may be unfamiliar with pharmacogenomic data.

Confirm that the laboratory is externally accredited and uses validated genotyping arrays. Check that results are interpreted against CPIC/DPWG guidelines specifically, not generic drug-interaction databases. Ask whether a prescriber summary letter is included — without it, your home doctor may not know how to act on the results. And verify that the specialist is available for follow-up communication with your prescriber if needed.

A personalised medication guide showing your metaboliser status for each tested enzyme, mapped against hundreds of medications. Each drug is categorised as standard use, use with caution, or consider alternative — with the specific genotype and guideline reference provided. A clinical summary letter translates the key findings for your prescribing physician.

Patients share the prescriber summary with their home doctor. The report becomes a permanent reference — consulted every time a new medication is considered, a dose is adjusted, or a reaction occurs. Some patients carry a summary card listing their most critical drug–gene interactions for emergency situations. The data never expires because your DNA does not change.

One to two days is sufficient. Sample collection and initial consultation are completed in a single 30-minute visit. Results are delivered remotely two to three weeks later. Many patients combine pharmacogenomic testing with DNA testing, health screening, or other genetic assessments during the same trip.

Your programme fee covers consultation, sample collection, accredited laboratory genotyping, drug–gene interaction analysis, personalised medication guide, specialist results consultation, prescriber summary letter, and a dedicated care coordinator. No special preparation is required.

Pharmacogenomic testing pairs efficiently with DNA testing and genetic risk assessment. Collecting samples for multiple tests during a single visit saves time and cost. Your coordinator schedules everything into a streamlined programme.